{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:22:57Z","timestamp":1789834977873,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009054","name":"U.S. President\u2019s Emergency Plan for AIDS Relief","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"name":"International Initiative for Impact Evaluation"},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01-AI095068"],"award-info":[{"award-number":["R01-AI095068"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R010161\/1"],"award-info":[{"award-number":["MR\/R010161\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01-GM136724"],"award-info":[{"award-number":["R01-GM136724"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Multi-assay algorithms (MAAs) are used to estimate population-level HIV incidence and identify individuals with recent infection. Many MAAs use low viral load (VL) as a biomarker for long-term infection. This could impact incidence estimates in settings with high rates of early HIV treatment initiation. We evaluated the performance of two MAAs that do not include VL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Samples were collected from 219 seroconverters (infected\u2009&lt;\u20091\u00a0year) and 4376 non-seroconverters (infected\u2009&gt;\u20091\u00a0year) in the HPTN 071 (PopART) trial; 28.8% of seroconverter samples and 73.2% of non-seroconverter samples had VLs\u2009\u2264\u2009400 copies\/mL. Samples were tested with the Limiting Antigen Avidity assay (LAg) and JHU BioRad-Avidity assays. Antibody reactivity to two HIV peptides was measured using the MSD U-PLEX assay. Two MAAs were evaluated that do not include VL: a MAA that includes the LAg-Avidity assay and BioRad-Avidity assay (LAg\u2009+\u2009BR) and a MAA that includes the LAg-Avidity assay and two peptide biomarkers (LAg\u2009+\u2009PepPair). Performance of these MAAs was compared to a widely used MAA that includes LAg and VL (LAg\u2009+\u2009VL).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The incidence estimate for LAg\u2009+\u2009VL (1.29%, 95% CI: 0.97\u20131.62) was close to the observed longitudinal incidence (1.34% 95% CI: 1.17\u20131.53). The incidence estimates for the other two MAAs were higher (LAg\u2009+\u2009BR: 2.56%, 95% CI 2.01\u20133.11; LAg\u2009+\u2009PepPair: 2.84%, 95% CI: 1.36\u20134.32). LAg\u2009+\u2009BR and LAg\u2009+\u2009PepPair also misclassified more individuals infected\u2009&gt;\u20092\u00a0years as recently infected than LAg\u2009+\u2009VL (1.2% [42\/3483 and 1.5% [51\/3483], respectively, vs. 0.2% [6\/3483]). LAg\u2009+\u2009BR classified more seroconverters as recently infected than LAg\u2009+\u2009VL or LAg\u2009+\u2009PepPair (80 vs. 58 and 50, respectively) and identified\u2009~\u200925% of virally suppressed seroconverters as recently infected.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The LAg\u2009+\u2009VL MAA produced a cross-sectional incidence estimate that was closer to the longitudinal estimate than two MAAs that did not include VL. The LAg\u2009+\u2009BR MAA classified the greatest number of individual seroconverters as recently infected but had a higher false recent rate.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07850-0","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T13:03:46Z","timestamp":1668171826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of multi-assay algorithms for cross-sectional HIV incidence estimation in settings with universal antiretroviral treatment"],"prefix":"10.1186","volume":"22","author":[{"given":"Wendy","family":"Grant-McAuley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Laeyendecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Monaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Hudelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Klock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Brookmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Piwowar-Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Ayles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Kosloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwame","family":"Shanaube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nomtha","family":"Mandla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneen","family":"van Deventer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Ruczinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Kammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Benjamin","family":"Larman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan H.","family":"Eshleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"issue":"3","key":"7850_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1093\/aje\/kws436","volume":"177","author":"R Brookmeyer","year":"2013","unstructured":"Brookmeyer R, Konikoff J, Laeyendecker O, Eshleman SH. Estimation of HIV incidence using multiple biomarkers. Am J Epidemiol. 2013;177(3):264\u201372.","journal-title":"Am J Epidemiol"},{"issue":"Suppl 2","key":"7850_CR2","doi-asserted-by":"publisher","first-page":"S233","DOI":"10.1097\/QAI.0b013e3182986fdf","volume":"63","author":"R Brookmeyer","year":"2013","unstructured":"Brookmeyer R, Laeyendecker O, Donnell D, Eshleman SH. Cross-sectional HIV incidence estimation in HIV prevention research. J Acquir Immune Defic Syndr. 2013;63(Suppl 2):S233\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"7850_CR3","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/infdis\/jis659","volume":"207","author":"O Laeyendecker","year":"2013","unstructured":"Laeyendecker O, Brookmeyer R, Cousins MM, Mullis CE, Konikoff J, Donnell D, et al. HIV incidence determination in the United States: a multiassay approach. J Infect Dis. 2013;207(2):232\u20139.","journal-title":"J Infect Dis"},{"issue":"7","key":"7850_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068349","volume":"8","author":"O Laeyendecker","year":"2013","unstructured":"Laeyendecker O, Piwowar-Manning E, Fiamma A, Kulich M, Donnell D, Bassuk D, et al. Estimation of HIV incidence in a large, community-based, randomized clinical trial: NIMH project accept (HIV Prevention Trials Network 043). PLoS ONE. 2013;8(7): e68349.","journal-title":"PLoS ONE"},{"issue":"5","key":"7850_CR5","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1016\/S2214-109X(14)70032-4","volume":"2","author":"TJ Coates","year":"2014","unstructured":"Coates TJ, Kulich M, Celentano DD, Zelaya CE, Chariyalertsak S, Chingono A, et al. Effect of community-based voluntary counselling and testing on HIV incidence and social and behavioural outcomes (NIMH Project Accept; HPTN 043): a cluster-randomised trial. Lancet Glob Health. 2014;2(5):e267\u201377.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"7850_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/infdis\/jis658","volume":"207","author":"SH Eshleman","year":"2013","unstructured":"Eshleman SH, Hughes JP, Laeyendecker O, Wang J, Brookmeyer R, Johnson-Lewis L, et al. Use of a multifaceted approach to analyze HIV incidence in a cohort study of women in the United States: HIV Prevention Trials Network 064 Study. J Infect Dis. 2013;207(2):223\u201331.","journal-title":"J Infect Dis"},{"issue":"12","key":"7850_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258644","volume":"16","author":"W Grant-McAuley","year":"2021","unstructured":"Grant-McAuley W, Klock E, Laeyendecker O, Piwowar-Manning E, Wilson E, Clarke W, et al. Evaluation of multi-assay algorithms for identifying individuals with recent HIV infection: HPTN 071 (PopART). PLoS ONE. 2021;16(12): e0258644.","journal-title":"PLoS ONE"},{"issue":"2","key":"7850_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114947","volume":"10","author":"YT Duong","year":"2015","unstructured":"Duong YT, Kassanjee R, Welte A, Morgan M, De A, Dobbs T, et al. Recalibration of the limiting antigen avidity EIA to determine mean duration of recent infection in divergent HIV-1 subtypes. PLoS ONE. 2015;10(2): e0114947.","journal-title":"PLoS ONE"},{"issue":"1","key":"7850_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1089\/aid.2009.0133","volume":"26","author":"X Wei","year":"2010","unstructured":"Wei X, Liu X, Dobbs T, Kuehl D, Nkengasong JN, Hu DJ, et al. Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein. AIDS Res Hum Retroviruses. 2010;26(1):61\u201371.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"7850_CR10","unstructured":"WHO\/UNAIDS. 2014. Annual meeting of the technical working group on HIV incidence assays. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/162156\/WHO_HIV_2015.11_eng.pdf;sequence=1. Accessed Sept 2021."},{"key":"7850_CR11","unstructured":"Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. WHO guidelines approved by the guidelines review committee. Geneva 2015. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK327115\/. Accessed Sept 2021."},{"key":"7850_CR12","unstructured":"WHO\/UNAIDS. 2015. Understanding Fast-Track: Accelerating action to end the AIDS epidemic by 2030. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/201506_JC2743_Understanding_FastTrack_en.pdf. Accessed Jun 2021."},{"issue":"7","key":"7850_CR13","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1089\/aid.2019.0286","volume":"36","author":"E Klock","year":"2020","unstructured":"Klock E, Mwinnya G, Eller LA, Fernandez RE, Kibuuka H, Nitayaphan S, et al. Impact of early antiretroviral treatment initiation on performance of cross-sectional incidence assays. AIDS Res Hum Retroviruses. 2020;36(7):583\u20139.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"10","key":"7850_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025899","volume":"6","author":"O Laeyendecker","year":"2011","unstructured":"Laeyendecker O, Latimore A, Eshleman SH, Summerton J, Oliver AE, Gamiel J, et al. The effect of sample handling on cross sectional HIV incidence testing results. PLoS ONE. 2011;6(10): e25899.","journal-title":"PLoS ONE"},{"issue":"8","key":"7850_CR15","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1097\/QAD.0000000000000221","volume":"28","author":"AF Longosz","year":"2014","unstructured":"Longosz AF, Mehta SH, Kirk GD, Margolick JB, Brown J, Quinn TC, et al. Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay. AIDS. 2014;28(8):1227\u201332.","journal-title":"AIDS"},{"issue":"4","key":"7850_CR16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1089\/aid.2016.0105","volume":"33","author":"SK Wendel","year":"2017","unstructured":"Wendel SK, Longosz AF, Eshleman SH, Blankson JN, Moore RD, Keruly JC, et al. Short communication: the impact of viral suppression and viral breakthrough on limited-antigen avidity assay results in individuals with clade B HIV infection. AIDS Res Hum Retroviruses. 2017;33(4):325\u20137.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"7850_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055525","volume":"8","author":"SK Wendel","year":"2013","unstructured":"Wendel SK, Mullis CE, Eshleman SH, Blankson JN, Moore RD, Keruly JC, et al. Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection. PLoS ONE. 2013;8(2): e55525.","journal-title":"PLoS ONE"},{"issue":"12","key":"7850_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25830","volume":"24","author":"E Klock","year":"2021","unstructured":"Klock E, Wilson E, Fernandez RE, Piwowar-Manning E, Moore A, Kosloff B, et al. Validation of population-level HIV-1 incidence estimation by cross-sectional incidence assays in the HPTN 071 (PopART) trial. J Int AIDS Soc. 2021;24(12): e25830.","journal-title":"J Int AIDS Soc"},{"issue":"3","key":"7850_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1814556","volume":"381","author":"RJ Hayes","year":"2019","unstructured":"Hayes RJ, Donnell D, Floyd S, Mandla N, Bwalya J, Sabapathy K, et al. Effect of universal testing and treatment on HIV incidence\u2014HPTN 071 (PopART). N Engl J Med. 2019;381(3):207\u201318.","journal-title":"N Engl J Med"},{"issue":"12","key":"7850_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082772","volume":"8","author":"J Konikoff","year":"2013","unstructured":"Konikoff J, Brookmeyer R, Longosz AF, Cousins MM, Celum C, Buchbinder SP, et al. Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States. PLoS ONE. 2013;8(12): e82772.","journal-title":"PLoS ONE"},{"issue":"8","key":"7850_CR21","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/QAD.0000000000002219","volume":"33","author":"S Sharma","year":"2019","unstructured":"Sharma S, Schlusser KE, de la Torre P, Tambussi G, Draenert R, Pinto AN, et al. The benefit of immediate compared with deferred antiretroviral therapy on CD4+ cell count recovery in early HIV infection. AIDS. 2019;33(8):1335\u201344.","journal-title":"AIDS"},{"key":"7850_CR22","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3389\/fimmu.2019.01062","volume":"10","author":"M Tuen","year":"2019","unstructured":"Tuen M, Bimela JS, Banin AN, Ding S, Harkins GW, Weiss S, et al. Immune correlates of disease progression in linked HIV-1 infection. Front Immunol. 2019;10:1062.","journal-title":"Front Immunol"},{"issue":"2","key":"7850_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/QAI.0b013e318214ba4a","volume":"57","author":"CS Morrison","year":"2011","unstructured":"Morrison CS, Chen PL, Nankya I, Rinaldi A, Van Der Pol B, Ma YR, et al. Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe. J Acquir Immune Defic Syndr. 2011;57(2):157\u201364.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"7850_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/QAD.0b013e3280117c8b","volume":"21","author":"CS Morrison","year":"2007","unstructured":"Morrison CS, Richardson BA, Mmiro F, Chipato T, Celentano DD, Luoto J, et al. Hormonal contraception and the risk of HIV acquisition. AIDS. 2007;21(1):85\u201395.","journal-title":"AIDS"},{"issue":"5","key":"7850_CR25","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.celrep.2019.03.097","volume":"27","author":"SH Eshleman","year":"2019","unstructured":"Eshleman SH, Laeyendecker O, Kammers K, Chen A, Sivay MV, Kottapalli S, et al. Comprehensive profiling of HIV antibody evolution. Cell Rep. 2019;27(5):1422-33.e4.","journal-title":"Cell Rep"},{"issue":"11","key":"7850_CR26","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1002\/sim.8920","volume":"40","author":"A Chen","year":"2021","unstructured":"Chen A, Laeyendecker O, Eshleman SH, Monaco DR, Kammers K, Larman HB, et al. A top scoring pairs classifier for recent HIV infections. Stat Med. 2021;40(11):2604\u201312.","journal-title":"Stat Med"},{"issue":"2","key":"7850_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25452","volume":"23","author":"SH Eshleman","year":"2020","unstructured":"Eshleman SH, Piwowar-Manning E, Wilson EA, Lennon D, Fogel JM, Agyei Y, et al. Determination of HIV status and identification of incident HIV infections in a large, community-randomized trial: HPTN 071 (PopART). J Int AIDS Soc. 2020;23(2): e25452.","journal-title":"J Int AIDS Soc"},{"key":"7850_CR28","unstructured":"Meso Scale Discovery. 2021. MULTI-ARRAY technology. https:\/\/www.mesoscale.com\/en\/technical_resources\/our_technology\/multi-array. Accessed 25 May 2021."},{"issue":"5","key":"7850_CR29","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1097\/EDE.0b013e3182576c07","volume":"23","author":"R Kassanjee","year":"2012","unstructured":"Kassanjee R, McWalter TA, Barnighausen T, Welte A. A new general biomarker-based incidence estimator. Epidemiology. 2012;23(5):721\u20138.","journal-title":"Epidemiology"},{"key":"7850_CR30","unstructured":"Grebe E, Welte A, McIntosh A, B\u00e4umler P and Ongarello S. inctools: incidence estimation tools. R package version 1.0.15. 2019. https:\/\/CRAN.R-project.org\/package=inctools. Accessed Aug 2021."},{"key":"7850_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/1467-985X.00049","volume":"160","author":"R Brookmeyer","year":"1997","unstructured":"Brookmeyer R. Accounting for follow-up bias in estimation of human immunodeficiency virus incidence rates. J Roy Stat Soc a Sta. 1997;160:127\u201340.","journal-title":"J Roy Stat Soc a Sta"},{"issue":"2","key":"7850_CR32","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/oxfordjournals.aje.a117404","volume":"141","author":"R Brookmeyer","year":"1995","unstructured":"Brookmeyer R, Quinn TC. Estimation of current human immunodeficiency virus incidence rates from a cross-sectional survey using early diagnostic tests. Am J Epidemiol. 1995;141(2):166\u201372.","journal-title":"Am J Epidemiol"},{"key":"7850_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25082","author":"O Laeyendecker","year":"2018","unstructured":"Laeyendecker O, Konikoff J, Morrison DE, Brookmeyer R, Wang J, Celum C, et al. Identification and validation of a multi-assay algorithm for cross-sectional HIV incidence estimation in populations with subtype C infection. J Int AIDS Soc. 2018. https:\/\/doi.org\/10.1002\/jia2.25082.","journal-title":"J Int AIDS Soc"},{"issue":"16","key":"7850_CR34","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1097\/QAD.0000000000000429","volume":"28","author":"R Kassanjee","year":"2014","unstructured":"Kassanjee R, Pilcher CD, Keating SM, Facente SN, McKinney E, Price MA, et al. Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. AIDS. 2014;28(16):2439\u201349.","journal-title":"AIDS"},{"issue":"6239","key":"7850_CR35","doi-asserted-by":"publisher","first-page":"0698","DOI":"10.1126\/science.aaa0698","volume":"348","author":"GJ Xu","year":"2015","unstructured":"Xu GJ, Kula T, Xu Q, Li MZ, Vernon SD, Ndungu T, et al. Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome. Science. 2015;348(6239):0698.","journal-title":"Science"},{"key":"7850_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.625941","volume":"11","author":"J Savoret","year":"2020","unstructured":"Savoret J, Mesnard JM, Gross A, Chazal N. Antisense transcripts and antisense protein: a new perspective on human immunodeficiency virus type 1. Front Microbiol. 2020;11: 625941.","journal-title":"Front Microbiol"},{"issue":"7","key":"7850_CR37","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1089\/aid.2019.0033","volume":"35","author":"E Gonese","year":"2019","unstructured":"Gonese E, Kilmarx PH, van Schalkwyk C, Grebe E, Mutasa K, Ntozini R, et al. Evaluation of the performance of three biomarker assays for recent HIV infection using a well-characterized HIV-1 subtype C incidence cohort. AIDS Res Hum Retroviruses. 2019;35(7):615\u201327.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"9","key":"7850_CR38","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1089\/aid.2016.0319","volume":"33","author":"JW Hargrove","year":"2017","unstructured":"Hargrove JW, van Schalkwyk C, Humphrey JH, Mutasa K, Ntozini R, Owen SM, et al. Short communication: heightened HIV antibody responses in postpartum women as exemplified by recent infection assays: implications for incidence estimates. AIDS Res Hum Retroviruses. 2017;33(9):902\u20134.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"4","key":"7850_CR39","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1089\/aid.2014.0081","volume":"31","author":"AF Longosz","year":"2015","unstructured":"Longosz AF, Morrison CS, Chen PL, Brand HH, Arts E, Nankya I, et al. Comparison of antibody responses to HIV infection in Ugandan women infected with HIV subtypes A and D. AIDS Res Hum Retroviruses. 2015;31(4):421\u20137.","journal-title":"AIDS Res Hum Retroviruses"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07850-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07850-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07850-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:03:10Z","timestamp":1668211390000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07850-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["7850"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07850-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"assertion":[{"value":"17 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from participants prior to enrollment in the GS Study and HPTN 071 (PopART) Population Cohort. The GS Study was approved by ethical review boards at FHI 360, Case Western University, University of California, San Francisco and in Uganda and Zimbabwe. The HPTN 071 (PopART) trial was approved by the institutional review board and ethics committees at the London School of Hygiene and Tropical Medicine, the University of Zambia, and Stellenbosch University. The research reported in this manuscript was performed using stored samples and was approved by the Institutional Review Board of the Johns Hopkins University of Medicine. Research was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"H.B.L. is an inventor on an issued patent (US20160320406A) filed by Brigham and Women\u2019s Hospital that covers the use of the VirScan technology, is a founder of ImmuneID, Portal Bioscience and Alchemab, and is an advisor to TScan Therapeutics. All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"838"}}